Altimmune(US:ALT) Globenewswire·2025-10-30 11:30Core Points - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [3] - The company will report its third quarter 2025 financial results on November 6, 2025 [1] - A conference call will be held on the same day at 8:30 a.m. ET to discuss the financial results and provide a business update [2] Company Overview - Altimmune's lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD), and obesity [3] - The company is committed to developing innovative treatments for significant health issues related to liver and cardiometabolic conditions [3]